Omniab (OABI) Slides 2.5% as Market Volatility Hits Biotech Valuations
Omniab (OABI) dips 2.51% amid market volatility—still trading above its 200‑day MA, with a bright antibody discovery pipeline poised for rebound. Read why investors should watch.
3 minutes to read